Associations between corrected serum calcium and phosphorus levels and outcome in dialysis patients in the Kumamoto Prefecture.
CKD-MBD
calcium
hemodialysis
mortality
phosphate
Journal
Hemodialysis international. International Symposium on Home Hemodialysis
ISSN: 1542-4758
Titre abrégé: Hemodial Int
Pays: Canada
ID NLM: 101093910
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
25
02
2019
revised:
21
01
2020
accepted:
26
01
2020
pubmed:
15
2
2020
medline:
20
11
2020
entrez:
15
2
2020
Statut:
ppublish
Résumé
Mortality in hemodialysis patients is relatively high; thus, its risk stratification is very important. There are insufficient data describing the current status of the management of serum phosphate and calcium levels. We conducted a multicenter, prospective, registry study throughout the Kumamoto Prefecture in Japan. We enrolled 1993 patients at 58 facilities with complete explanatory data, including serum phosphate, corrected calcium, and intact parathyroid hormone levels. We categorized subjects into nine categories according to low, normal, and high levels of phosphate and corrected calcium levels. The endpoint was all-cause mortality. Of the total number of subjects, 56.1% of the patients were in the normal phosphate and calcium category, and 72% and 77.1% had controlled serum phosphate and calcium levels, respectively. Two hundred twenty-six deaths occurred during the follow-up period. In the nine categories, the highest mortality rates were observed in the highest corrected calcium and lowest phosphate categories. Stepwise backward multivariate regression analyses identified the serum corrected calcium level (OR, 1.38; 95% CI, 1.06-1.79; P = 0.016) and the serum phosphate level (OR, 1.26; 95% CI, 1.08-1.48; P = 0.003) as significant and independent predictors of all-cause mortality. The corrected serum calcium and phosphate levels are associated with mortality in our dialysis population, with poorest survival in patients with high corrected serum calcium and low serum phosphorus.
Substances chimiques
Phosphorus
27YLU75U4W
Calcium
SY7Q814VUP
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
202-211Informations de copyright
© 2020 International Society for Hemodialysis.
Références
Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: The Hisayama study. Kidney Int. 2005;68:228-236.
Nagata M, Ninomiya T, Doi Y, et al. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: The Hisayama study. Nephrology Dialysis Transplantation. 2010;25:2557-2564.
Publishing O. Health at a Glance 2013: OECD Indicators. Paris, France: OECD Publishing, 2013.
Hokimoto S, Sakamoto K, Akasaka T, et al. High mortality rate in Hemodialysis patients who undergo invasive cardiovascular procedures related to peripheral artery disease-community-based observational study in Kumamoto prefecture. Circ J. 2015;79:1269-1276.
Sueta D, Hokimoto S, Sakamoto K, et al. Validation of the high mortality rate of malnutrition-inflammation-atherosclerosis syndrome:-community-based observational study. Int J Cardiol. 2017;230:97-102.
Sueta D, Yamamoto E, Hirata Y, et al. Novel vascular indices evaluated non-invasively in end-stage renal disease patients on hemodialysis. Clinical Trials and Regulatory Science in Cardiology. 2015;9:1-3.
Group KDIGOC-MW. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-130.
Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17:247-288.
Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945-1953.
Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters. Kidney Int. 2017;92:26-36.
Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:1-201.
Kasiske B, Cosio FG, Beto J, et al. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(Suppl 3):S1-91.
Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913-921.
Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005;20:2186-2193.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218.
Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis. 2005;46:68-77.
Noordzij M, Korevaar J, Boeschoten E, et al. The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: Association with mortality in dialysis patients. Am J Kidney Dis. 2005;46:925-932.
Kalantar-Zadeh K, Kuwae N, Regidor D, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771-780.
Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2010;26:1948-1955.
Taniguchi M, Fukagawa M, Fujii N, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013;17:221-228.
Payne R, Little A, Williams R, Milner J. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4:643-646.
Sueta D, Tabata N, Ikeda S, et al. Differential predictive factors for cardiovascular events in patients with or without cancer history. Medicine (Baltimore). 2019;98:e17602.
Rubin DB, Schenker N. Multiple imputation in health-care databases: An overview and some applications. Stat Med. 1991;10:585-598.
Sueta D, Hokimoto S, Utsunomiya D, et al. New aspects of onco-cardiology. Int J Cardiol. 2016;206:68-70.
Simons DB, Schwartz RS, Edwards WD, Sheedy PF, Breen JF, Rumberger JA. Noninvasive definition of anatomic coronary artery disease by ultrafast computed tomographic scanning: A quantitative pathologic comparison study. J Am Coll Cardiol. 1992;20:1118-1126.
Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: Observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860-1870.
Yamamoto H, Kitagawa T, Kihara Y. Clinical implications of the coronary artery calcium score in Japanese patients. J Atheroscler Thromb. 2014;21:1101-1108.
Nagano N. Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther. 2006;109:339-365.
Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793-1800.
Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627-2633.
Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant. 2000;15:953-960.
Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156:556-563.
Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20:381-387.
Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592.
Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52:519-530.
Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73:391-398.